MedTrace Logo

Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

NCT00092963 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 529

Last updated 2024-08-14

No results posted yet for this study

Summary

The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.

Conditions

Interventions

DRUG

MK0462, rizatriptan benzoate / Duration of Treatment: 1day

DRUG

Comparator: placebo / Duration of Treatment: 1 day

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-17
Primary Completion
2005-01-14
Completion
2005-01-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092963 on ClinicalTrials.gov